CLINICAL UPDATES · SEASON 1 · EPISODE 3
CKD–Mineral and Bone Disorder
As kidneys fail, the tightly linked system that balances phosphate, calcium, vitamin D, and parathyroid hormone (PTH) unravels — affecting bones, blood vessels, and the heart. This is CKD–mineral and bone disorder (CKD-MBD). This Clinical Update explains the hormonal cascade behind it, what clinicians monitor, and the principles behind phosphate control, vitamin D therapy, and PTH management.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
MedicalVideos Clinical Updates is an educational series produced with full editorial independence. If an episode is sponsor-funded, that funding is labelled on the episode page and on the series hub.
The update
The clinical picture
The earliest change is hormonal: fibroblast growth factor 23 (FGF23) rises to force phosphate excretion, suppressing active vitamin D in the process. With less active vitamin D, gut calcium absorption falls; retained phosphate and low calcium then stimulate the parathyroid glands. Secondary hyperparathyroidism develops — PTH keeps blood calcium up by dissolving bone. Over years this produces the spectrum of renal bone disease, from high-turnover bone loss to oversuppressed, adynamic bone, while calcium and phosphate deposit in vessels and soft tissues, stiffening arteries. CKD-MBD is therefore a bone, mineral, and cardiovascular disorder at once.
The current landscape
Guideline practice, led by KDIGO's CKD-MBD guideline, is trend-based: phosphate, calcium, and PTH are interpreted together and over time rather than as isolated numbers. Phosphate control starts with diet — particularly phosphate additives in processed food — and phosphate binders taken with meals; binder choice balances calcium load, cost, and tolerance. Vitamin D strategy separates nutritional vitamin D repletion from active vitamin D analogues used to control PTH, and calcimimetics, which lower PTH by acting on the parathyroid calcium-sensing receptor, are established in dialysis care. Dialysis itself removes phosphate inefficiently, which is why diet and binders stay central even after dialysis starts.
In practice
Monitoring typically begins in moderate CKD and intensifies with stage: phosphate, calcium, PTH, alkaline phosphatase, and vitamin D status, at intervals set by stage and previous results. Dietary phosphate counselling targets additives — ingredients with 'phos' in the name — rather than banning nutritious protein foods outright. Binder adherence is a practical challenge because the pills must travel with meals; reviewing the regimen at clinic visits matters as much as the prescription. Persistent severe hyperparathyroidism despite medical therapy raises the question of parathyroidectomy, decided jointly by nephrology and endocrine surgery.
When to escalate
Escalate when calcium climbs high — particularly with a suppressed PTH, which suggests calcium overload or adynamic bone — and when phosphate stays uncontrolled despite diet and binders. Bone pain, fractures from minor trauma, non-healing skin lesions, or suspected calcific uremic arteriolopathy (calciphylaxis) need urgent specialist assessment; calciphylaxis is rare but life-threatening. In children, growth failure is an escalation trigger of its own. Any abrupt change in calcium after starting or stopping vitamin D analogues or calcimimetics should prompt early rechecking rather than waiting for the next routine panel.
Common questions
What is secondary hyperparathyroidism?
It is overactivity of the parathyroid glands driven by kidney failure: phosphate retention and low active vitamin D push the glands to release more parathyroid hormone. The hormone keeps blood calcium normal at the cost of dissolving bone, so it is 'secondary' to the kidney problem.
Why does phosphate matter if I feel fine?
High phosphate rarely causes symptoms at first, but over years it drives parathyroid overactivity, weakens bone, and contributes to calcium deposits in blood vessels. Controlling it early — diet, then binders with meals — is preventive, not symptom-driven.
Are all phosphate binders the same?
No. Binders differ in whether they contain calcium, their pill burden, cost, and side effects. The choice is individualised: total calcium intake matters, because excess calcium-based binder can add to vascular calcification, while non-calcium binders may cost more or be harder to obtain.
Can CKD bone disease be reversed?
The hormonal drivers can be controlled and bone turnover brought back toward normal, especially when treatment starts before severe parathyroid overgrowth. Established vascular calcification is much harder to reverse, which is why guidelines emphasise early, steady, trend-based management.
More in Chronic Kidney Disease Care
Related
Related reading
Sources
- CKD–Mineral and Bone Disorder Guideline (KDIGO)
- Chronic Kidney Disease (MedlinePlus, US National Library of Medicine)
- Chronic Kidney Disease (CKD) (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))
- CKD Evaluation and Management Guideline (KDIGO)
This Clinical Update is educational content for clinicians and informed patients. It is not medical advice and does not replace the judgment of the treating team. Drug classes are discussed in general terms only; prescribing decisions, doses, and monitoring belong with the patient's own clinicians. Mineral targets are individualised in current guidelines; single results should always be read as part of a trend.